Last reviewed · How we verify

Bendamustine-EAM — Competitive Intelligence Brief

Bendamustine-EAM (Bendamustine-EAM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent (as part of EAM conditioning regimen). Area: Oncology.

phase 2 Alkylating agent (as part of EAM conditioning regimen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bendamustine-EAM (Bendamustine-EAM) — Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bendamustine-EAM TARGET Bendamustine-EAM Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea phase 2 Alkylating agent (as part of EAM conditioning regimen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent (as part of EAM conditioning regimen) class)

  1. Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bendamustine-EAM — Competitive Intelligence Brief. https://druglandscape.com/ci/bendamustine-eam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: